Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

GLP-1 diet study: what happens when you eat on ozempic?

NCT ID NCT07001553

Knowledge-focused Sponsor: Australian Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how people change their eating habits after starting GLP-1 drugs like Ozempic or Mounjaro for weight or diabetes. Researchers tracked 37 adults using dietary records and questionnaires to see if it's feasible to study diet changes this way. The goal was to understand recruitment and retention, not to test the drugs themselves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 agonist (e.g., Ozempic, Trulicity, Mounjaro, Saxenda)
What this could lead to
If successful, this could help doctors understand how diet changes with these medications, leading to better dietary advice for patients.
What could go wrong
This is a small, completed feasibility study with only 37 participants, so results may not apply broadly. It only observed dietary patterns, not treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

37 people

The number who actually took part.

Started

May 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals living in Australia who are intending to commence a GLP-1 prescription

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18+ years old * Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months * The primary reason for commencing the medication will be for diabetes or weight management * Willing to participate in dietary recall and questionnaires Exclusion Criteria: * Aged under 18 years, * used a GLP-1 agonist medication in the previous 6 months, * unwilling or unable to provide dietary recalls * non-English speaking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Australian Catholic University

    Fitzroy, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.